LB Pharmaceuticals Strengthens Regulatory Leadership with James Rawls Appointment Ahead of LB-102 Phase 3 Trial
核心洞察
LB Pharmaceuticals (搜索) has appointed James Rawls (搜索), Pharm.D., as Senior Vice President of Regulatory Affairs to support the advancement of LB-102 into Phase 3 trials for schizophrenia (搜索) and Phase 2 trials for bipolar depression (搜索) in 2026.
Dr. Rawls brings over 25 years of regulatory leadership experience and has led or contributed to more than a dozen successful regulatory filings and product approvals in the United States, Europe, and Japan, with specific expertise in neuropsychiatric diseases.
LB-102, a methylated derivative of amisulpride, demonstrated statistically significant benefits versus placebo at all doses studied in a Phase 2 trial for acute schizophrenia (搜索), with a potentially class-leading safety profile among D2 antagonists and partial agonists.
LB Pharmaceuticals (搜索) Inc (Nasdaq: LBRX) has appointed James Rawls (搜索), Pharm.D., as Senior Vice President of Regulatory Affairs, positioning the company for critical Phase 3 advancement of its lead neuropsychiatric candidate LB-102. The strategic hire comes as the clinical-stage biopharmaceutical company prepares to advance LB-102 into a Phase 3 clinical trial in schizophrenia (搜索) and a Phase 2 clinical trial in bipolar depression (搜索) in 2026.
Regulatory Expertise for Neuropsychiatric Development
Dr. Rawls brings extensive regulatory leadership experience spanning more than 25 years across global biopharmaceutical companies. Throughout his career, he has led or contributed to more than a dozen successful regulatory filings and product approvals in the United States, Europe, and Japan, with specific experience in neuropsychiatric diseases.
"Dr. Rawls has a remarkable depth of regulatory expertise that will be instrumental as we advance LB-102 into a Phase 3 clinical trial in schizophrenia (搜索) and a Phase 2 clinical trial in bipolar depression (搜索) in 2026," said Heather Turner (搜索), Chief Executive Officer of LB Pharmaceuticals (搜索). "His experience leading successful FDA and global regulatory engagements, particularly in neuropsychiatry, will be invaluable as we continue to execute on our work to make LB-102 the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States."
Distinguished Career in Regulatory Affairs
Dr. Rawls joins LB Pharmaceuticals (搜索) from Boston Biodevelopment (搜索), LLC, where he served as Executive Vice President and Chief Regulatory Officer, leading regulatory strategy and execution for multiple small and mid-sized biopharma clients. His previous roles include senior regulatory leadership positions at Sumitomo Pharma America (搜索), where he built and oversaw a regulatory team of more than 60 employees following the integration of seven subsidiaries, including Sunovion (搜索).
During his 15-year tenure at Sunovion (搜索), Dr. Rawls led the Global Regulatory Affairs function and supported numerous global product approvals and lifecycle expansions across multiple therapeutic areas. He also spent over a decade in increasingly senior regulatory roles at Novartis. Dr. Rawls is a Doctor of Pharmacy graduate from the University of Michigan and completed a postdoctoral fellowship in Regulatory Affairs and Clinical Research at Novartis and Rutgers University.
LB-102 Clinical Development Program
LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals (搜索) announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia (搜索). The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition.
The drug candidate is advancing into a Phase 3 clinical trial for acute schizophrenia (搜索) and a Phase 2 clinical trial for bipolar depression (搜索). Additional expansion opportunities for LB-102 could include major depressive disorder (搜索) (MDD), predominantly negative symptoms of schizophrenia, Alzheimer's disease (搜索) psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia.
Strategic Vision for Neuropsychiatric Treatment
"The complexity of neuropsychiatric drug development demands thoughtful, evidence-driven regulatory strategy that is bold but pragmatic," Dr. Rawls commented. "I'm energized by LB Pharmaceuticals (搜索)' mission and look forward to working with the highly skilled and experienced team at LB Pharmaceuticals as we advance LB-102 in the clinic with the goal of delivering a new treatment option for patients with neuropsychiatric disorders."
LB Pharmaceuticals (搜索) is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. If approved, LB-102 has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia (搜索), bipolar depression (搜索), and other neuropsychiatric diseases.